Literature DB >> 8722372

Tunneled, double lumen Broviac catheters are useful, efficient and safe in children undergoing peripheral blood progenitor cell harvesting and transplantation.

K Leibundgut1, C Müller, K Müller, A Ridolfi-Lüthy, A Hirt.   

Abstract

We prospectively evaluated performance, efficiency, safety and compliance of large-bore central venous catheters (Cook TPN; Cook (Switzerland) AG) introduced via saphenous veins in 32 children and infants elected to undergo peripheral blood progenitor cell (PBPC) harvesting and transplantation (PBPCT). With these catheters a flow rate (25-65 ml/min) adequate for leukapheresis was achieved in all patients. There were no important catheter-related complications during harvest. The total duration of catheter placement was 4569 days (median, 139 days; range, 8-268 days). During this period which included conditioning and PBPCT, we observed five mechanical complications and 12 septic episodes not necessarily catheter-related (0.11 and 0.26 events per 100 catheter days, respectively). All infections resolved after systemic antibiotic treatment. There was no exit or tunnel area infection, and no catheter had to be removed due to infection. Two catheters were replaced because of displacement. Tunneled double lumen Broviac catheters introduced via saphenous veins were not only efficient and safe, they were also well accepted by children and young adults undergoing PBPC harvesting and transplantation.

Entities:  

Mesh:

Year:  1996        PMID: 8722372

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

Review 1.  A narrative review of long-term central venous access devices for the intensivist.

Authors:  David Moir; Andrew Bodenham
Journal:  J Intensive Care Soc       Date:  2017-12-12

2.  Catheter-related bloodstream infection in patients with motility disorder of the alimentary tract.

Authors:  Wataru Sumida; Yoshio Watanabe; Hidemi Takasu; Kazuo Oshima
Journal:  Pediatr Surg Int       Date:  2014-07-22       Impact factor: 1.827

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.